| # | Title | Journal | Year | Citations |
|---|
| 1 | Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer | New England Journal of Medicine | 2018 | 4,701 |
| 2 | Guidelines for the use and interpretation of assays for monitoring autophagy | Autophagy | 2012 | 3,122 |
| 3 | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial | Lancet Oncology, The | 2015 | 2,353 |
| 4 | Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation | Cancer Cell | 2010 | 2,328 |
| 5 | Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual | Ca-A Cancer Journal for Clinicians | 2017 | 1,662 |
| 6 | Chimeric antigen receptor T-cell therapy — assessment and management of toxicities | Nature Reviews Clinical Oncology | 2018 | 1,659 |
| 7 | Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma | JAMA - Journal of the American Medical Association | 2017 | 1,619 |
| 8 | The Draft Genome of Ciona intestinalis: Insights into Chordate and Vertebrate Origins | Science | 2002 | 1,539 |
| 9 | Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial | Lancet Oncology, The | 2019 | 1,467 |
| 10 | Erasers of Histone Acetylation: The Histone Deacetylase Enzymes | Cold Spring Harbor Perspectives in Biology | 2014 | 1,346 |
| 11 | Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy | New England Journal of Medicine | 2016 | 1,140 |
| 12 | Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer | New England Journal of Medicine | 2021 | 1,042 |
| 13 | Chromosomal instability drives metastasis through a cytosolic DNA response | Nature | 2018 | 1,002 |
| 14 | Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma | JAMA - Journal of the American Medical Association | 2015 | 982 |
| 15 | Epidemiology of ovarian cancer: a review | Cancer Biology and Medicine | 2017 | 981 |
| 16 | Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study | Lancet, The | 2016 | 962 |
| 17 | Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial | Lancet Oncology, The | 2017 | 921 |
| 18 | Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial | Lancet, The | 2019 | 879 |
| 19 | Imaging biomarker roadmap for cancer studies | Nature Reviews Clinical Oncology | 2017 | 792 |
| 20 | The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression | Cold Spring Harbor Perspectives in Medicine | 2016 | 777 |
| 21 | Palliative Radiotherapy for Bone Metastases: An ASTRO Evidence-Based Guideline | International Journal of Radiation Oncology Biology Physics | 2011 | 765 |
| 22 | Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma | JAMA Oncology | 2017 | 750 |
| 23 | Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2020 | 710 |
| 24 | Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes | Clinical Cancer Research | 2016 | 705 |
| 25 | Adaptive Therapy | Cancer Research | 2009 | 701 |
| 26 | Screening for psychologic distress in ambulatory cancer patients | Cancer | 2005 | 696 |
| 27 | American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update | Journal of the American College of Surgeons | 2017 | 664 |
| 28 | Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci | Nature Genetics | 2018 | 652 |
| 29 | Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial | Lancet Oncology, The | 2016 | 574 |
| 30 | Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study | Lancet Oncology, The | 2020 | 544 |
| 31 | A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma | Clinical Cancer Research | 2009 | 531 |
| 32 | Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial | Lancet, The | 2016 | 529 |
| 33 | Repeatability and Reproducibility of Radiomic Features: A Systematic Review | International Journal of Radiation Oncology Biology Physics | 2018 | 527 |
| 34 | Toxicities of Immunotherapy for the Practitioner | Journal of Clinical Oncology | 2015 | 521 |
| 35 | The Health Belief Model as an Explanatory Framework in Communication Research: Exploring Parallel, Serial, and Moderated Mediation | Health Communication | 2015 | 504 |
| 36 | Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma | Molecular Therapy | 2017 | 498 |
| 37 | Targeting protein prenylation for cancer therapy | Nature Reviews Cancer | 2011 | 497 |
| 38 | Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system | Annals of Oncology | 2004 | 486 |
| 39 | Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium | Journal of Clinical Oncology | 2020 | 481 |
| 40 | Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors | Cancer Cell | 2019 | 475 |
| 41 | Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer | JAMA Oncology | 2020 | 419 |
| 42 | A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer | Nature Genetics | 2014 | 408 |
| 43 | Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs | Cancer Treatment Reviews | 2017 | 398 |
| 44 | Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial | Lancet Oncology, The | 2018 | 398 |
| 45 | Isolation and Characterization of cDNAs Corresponding to an Additional Member of the Human Histone Deacetylase Gene Family | Journal of Biological Chemistry | 1997 | 396 |
| 46 | Classification of current anticancer immunotherapies | Oncotarget | 2014 | 395 |
| 47 | Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis | Blood | 2014 | 382 |
| 48 | The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update | Clinical Pharmacology and Therapeutics | 2014 | 379 |
| 49 | A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study | Lancet Oncology, The | 2017 | 377 |
| 50 | Cancer therapy shapes the fitness landscape of clonal hematopoiesis | Nature Genetics | 2020 | 367 |
